aTyr Pharma to Present at September Investor Conferences
Details of the events are as follows:
Conference: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
A replay of the live webcast of each presentation will be available on the Investor’s section of the Company’s website at www.atyrpharma.com, and will be available for 90 days following each event.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
|Investor Relations, aTyr Pharma|
Source: aTyr Pharma, Inc.